
Industry
Biotechnology
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Loading...
Open
38.00
Mkt cap
2.4B
Volume
296K
High
39.20
P/E Ratio
-20.40
52-wk high
58.26
Low
37.84
Div yield
N/A
52-wk low
36.52
Portfolio Pulse from Vandana Singh
July 17, 2023 | 12:38 pm
Portfolio Pulse from richadhand@benzinga.com
July 17, 2023 | 10:18 am
Portfolio Pulse from Benzinga Newsdesk
July 14, 2023 | 7:40 pm
Portfolio Pulse from Happy Mohamed
July 14, 2023 | 7:39 pm
Portfolio Pulse from Chris Katje
July 10, 2023 | 2:07 pm
Portfolio Pulse from Lisa Levin
July 06, 2023 | 12:58 pm
Portfolio Pulse from Benzinga Insights
July 04, 2023 | 9:37 pm
Portfolio Pulse from Benzinga Insights
July 03, 2023 | 3:01 pm
Portfolio Pulse from Chris Katje
July 03, 2023 | 2:18 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.